Plasma adiponectin is related to the progression of kidney disease in type 2 diabetes patients

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 72, Issue 4, 2012, Pages 333-339

  Kacso, Ina Maria ^a   Bondor, Cosmina Ioana ^a   Kacso, Gabriel ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Adipokines; Albuminuria; Diabetic nephropathies; Disease progression; Inflammation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ALBUMINURIA; ARTICLE; BODY MASS; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED;

EID: 84862859158     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2012.668928     Document Type: Article

References (51)

1. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V,Murphy BD, Palin MF. Adiponectin action from head to toe.Endocrine 2010;37:11-32.
2. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 2002;13:84-9.
3. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y,Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol. Metab. 2001;86:1930-5.
4. Costacou T, Zgibor JC, Evans RW, Otvos J, Lopes-Virella MF, Tracy RP, Orchard TJ. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2005;48:41-8.
5. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH,Rewers M. Low plasma adiponectin levels predict progression of coronary artery calcifi cation. Circulation 2005;111:747-53.
6. Schulze MB, Shai I, Rimm EB, Wadwa P, Snell-Bergeon JK,Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M.Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54:534-9.
7. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB,Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
8. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007;74:11-8.
9. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005;20:129-34.
10. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH,Stehouwer CD. EURODIAB Prospective Complications Study Group. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol. Metab. 2006;91:129-35.
11. Komaba H, Igaki N, Goto S, Yokota K, Doi H, Takemoto T,Kohno M, Hirosue Y, Goto T. Increased serum highmolecular- weight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol 2006;26:476-82.
12. Barlovic DP, Zaletel J, Prezelj J. Adipocytokines are associated with renal function in patients with normal range glomerular fi ltration rate and type 2 diabetes. Cytokine 2009;46:142-5.
13. Saraheimo M, Forsblom C, Thorn L, Teppo AM,Pettersson-Fernholm K, Frystyk J, Flyvbjerg A, Groop PH.Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005;28:1410-4.
14. Bakkaloglu SA, Soylemezoglu O, Buyan N, Funahashi T,Elhan AH, Peru H, Fidan K, Yilmaz S, Hasanoglu E. High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse. Pediatr Nephrol 2005;20:474-7.
15. Shimotomai T, Kakei M, Narita T, Koshimura J, Hosoba M,Kato M, Komatsuda A, Ito S. Enhanced urinary adiponectin excretion in IgA-nephropathy patients with proteinuria.Ren Fail 2005;27:323-8.
16. Oguz Y, Yilmaz MI, Acikel C, Eyileten T, Caglar K, Oktenli C, Yenicesu M, Vural A. The relationship between adiponectin levels and degree of proteinuria in patients with nephrotic and nonnephrotic proteinuria. Ren Fail 2009;31:29-35.
17. Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S,Parlongo S, Catalano F, Tanaka S, Ouchi N, Kihara S,Funahashi T, Matsuzawa Y. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int 2003;98-102.
18. Ohashi K, Iwatani H, Kihara S, Nakagawa Y, Komura N,Fujita K, Maeda N, Nishida M, Katsube F, Shimomura I,Ito T, Funahashi T. Exacerbation of albuminuria and renal fi brosis in subtotal renal ablation model of adiponectinknockout mice. Arterioscler Thromb Vasc Biol 2007;27:1910-17.
19. Sharma K, Ramachandrarao S, Qiu, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B,Goldstein BJ. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008;118:1645-56.
20. Kacso I, Lenghel A, Bondor CI, MoldoVan D, Rusu C,Nita C, Kacso G, Hancu N, Caprioara MG. Low plasma adiponectin levels predict increased urinary albumin/creatinine ratio in type 2 diabetes patients. Int Urol Nephrol 2011 Oct 13 [Epub ahead of print].
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D.A more accurate method to estimate glomerular fi ltration rate from serum creatinine: a new prediction equation. Modifi cation of Diet in Renal Disease Study Group. Ann Intern Med 1999;16;130:461-70.
22. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular fi ltration rate. Ann Intern Med 2009;150:604-12.
23. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:131-41.
24. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-75.
25. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G,Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S,Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-41.
26. Ramos LF, Shintani A, Himmelfarb J, Ikizler TA. Determinants of plasma adiponectin levels in nondiabetic subjects with moDerate to severe chronic kidney disease. J Ren Nutr 2009;19:197-203.
27. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M,Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K,Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K,Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel,adipose-specifi c protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
28. Saraheimo M, Forsblom C, Thorn L, Wadeí n J, Rosengård- Bärlund M, Heikkilä O, Hietala K, Gordin D, Frystyk J,Flyvbjerg A, Groop PH; FinnDiane Study Group. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008;31:1165-9.
29. Lin J, Hu FB, Curhan G. Serum adiponectin and renal dysfunction in men with type 2 diabetes. Diabetes Care 2007;30:239-44.
30. Yano Y, Hoshide S, Ishikawa J, Hashimoto T, Eguchi K, Shimada K, Kario K. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J Clin Hypertens (Greenwich) 2007;9:775-82.
31. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F:MMKD Study Group. GenDer-specifi c association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to MoDerate Kidney Disease Study.Kidney Int 2007;71:1279-86.
32. Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, Vionnet N, Rossing. Serum adiponectin predicts allcause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008;74:649-54.
33. Pilz S, Mangge H, Wellnitz B, Seelhorst U, Winkelmann BR,Tiran B, Boehm BO, M ärz W. Adiponectin and mortality in patients unDergoing coronary angiography. J Clin Endocrinol. Metab. 2006;91:4277-86.
34. Maiolino G, Cesari M, Sticchi D, Zanchetta M, Pedon L,Antezza K, Pessina AC, Rossi GP. Plasma adiponectin for prediction of cardiovascular events and mortality in highrisk patients. J Clin Endocrinol. Metab. 2008;93:3333-40.
35. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J,Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure.Circulation 2005;112:1756-62.
36. Menon V, Li L, Wang X, Greene T, Balakrishnan V, MaDero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, Levey AS,Sarnak MJ. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2599-606.
37. Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J Ren Nutr 2011;21:82-6.
38. Richards AA, Stephens T, Charlton HK, Jones A,Macdonald GA, Prins JB, Whitehead JP. Adiponectin multimerization is dependent on conserved lysines in thecollagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifi cations. Mol Endocrinol 2006;20:1673-87.
39. Zoccali C, Mallamaci F. Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers? J Ren Nutr 2011;21:87-91.
40. Zoccali C, Mallamaci F. Adiponectin and renal disease progression: another epidemiologic conundrum? Kidney Int 2007;71:1195-7.
41. Jaziri R, Aubert R, Roussel R, Emery N, Maimaitiming S,Bellili N, Miot A, Saulnier PJ, Travert F, Hadjadj S, Marre M, Fumeron F; DIABHYCAR and SURDIAGENE Study Groups. Association of ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 diabetes. Nephrol Dial Transplant 2010;25:2231-7.
42. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T,Aso Y, Inukai T, Okuno T, Node K. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 2007;100:569-74.
43. Narita K, Murata T, Hamada T, Takahashi T, Kosaka H,Sudo S, Mizukami K, Yoshida H, Wada Y. Adiponectin multimer distribution, not absolute amount of plasma, correlates with depression severity in healthy elDerly subjects. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:124-7.
44. Devaraj S, Torok N, Dasu MR, Samols D, Jialal I. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 2008;28:1368-74.
45. von Eynatten M, Liu D, Hock C, Oikonomou D, Baumann M, Allolio B, Korosoglou G, Morcos M, Campean V, Amann K, Lutz J, Heemann U, Nawroth PP, Bierhaus A, Humpert PM. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes 2009;58:2093-9.
46. Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K, Chan L, Goldstein BJ, Scalia R. Adiponectin defi ciency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007;117:1718-26.
47. Nakamaki S, Satoh H, Kudoh A, Hayashi Y, Hirai H,Watanabe T. Adiponectin reduces proteinuria in streptozotocin-induced diabetic Wistar rats. Exp Biol Med (Maywood) 2011;236:614-20.
48. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K,Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008;23:1621-7.
49. Lin J, Glynn R, Rifai N, Manson J, Ridker PM, Nathan DM,Schaumberg DA. Infl ammation and progressive nephropathy in type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2338-43.
50. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009;76:145-8.
51. Zoccali C, Mallamaci F. Obesity, diabetes, adiponectin and the kidney: a podocyte affair. Nephrol Dial Transplant 2008;23:3767-70.